- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01099215
Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH) (TRIUMPH)
An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label dose escalation safety study of PVS-10200 in 30 subjects with peripheral artery disease (PAD) requiring balloon angioplasty and stent placement in the superficial femoral artery (SFA). The study will be completed sequentially in two dose cohorts of 10 subjects (low dose group, Cohort A) and 20 subjects (high dose group, Cohort B). A Data Safety Monitoring Board (DSMB) will conduct regular safety reviews.
Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection to the perivascular region (external to the vessel) of the stented target lesion. The treatment will be administered within 24 hours after balloon angioplasty/stent placement.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- Centre Hospitalier Universitaire d'Amiens
-
Paris, France, 75015
- Hopital Europeen Georges Pompidou
-
Paris, France, 75018
- Hôpital Bichat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject has signed the informed consent document and patient information leaflet.
- Male and female subject ≥ 18 years of age at the time of consent.
- If female, the subject is (a) at least 1 year post-menopausal, or (b) surgically sterile, or (c) of child-bearing potential, with a negative serum pregnancy test result prior to study enrollment, who agrees to use adequate contraception for 6 months. Adequate contraception is defined as abstinence or a reliable method of birth control (e.g., a hormonal contraceptive, intra-uterine device, implantable or injectable contraceptives (Norplant® or Depo-Provera®), diaphragm, or condom with spermicide).
- Subject has symptomatic peripheral arterial disease involving the superficial femoral artery, defined as Fontaine Class IIb, III and IV.
Meets anatomic requirements based on biplane digital subtraction angiography performed at the time of intervention including:
- Stenosis of ≥ 50% or occlusion of the superficial femoral artery, and
- Target lesion length of ≤ 150 mm, and
- At least one patent (< 50 % stenosis) tibioperoneal runoff vessel
- Target lesion is 7-15 cm in length.
- Subject is expected to stay in the same geographic area for at least 48 weeks.
- In the opinion of the investigator, the subject is able to understand and is willing to complete the study requirements.
- Subject is receiving a therapeutic dose of statin therapy (starting minimum of 7 days prior to intervention) and continuing for a minimum of 4 weeks post-intervention.
Exclusion Criteria:
- Subject has acute limb ischemia.
- Subject has had prior revascularization of the target lesion.
- Subject has untreated inflow disease of the ipsilateral pelvic arteries (> 50% stenosis or occlusion).
- The target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s).
- Subject has an unresolved thrombus within the target vessel.
- Additional percutaneous interventional procedures (cardiac/peripheral) are planned ≤ 30 days following the study procedure.
- Subject has suffered a hemorrhagic stroke ≤ 6 mo prior to the study procedure.
- Subject has a history of bleeding diatheses or coagulopathy.
- Subject is diagnosed with septicemia at the time of the study procedure.
- Subject is known to be seropositive for HIV.
- Subject has some other medical illness that may cause the subject to be non-compliant with the protocol.
- Subject has a known allergy to bovine or porcine products (i.e., heparin).
- Subject has a known allergy to collagen/gelatin products.
- Subject has had a severe reaction to contrast media.
- Subject has a known allergy or intolerance to anti-platelet medication (e.g., acetylsalicylic acid or clopidogrel) or statin therapy.
- Subject has a history of IV drug use within 6 months prior to screening.
- Subject has a documented diagnosis of cancer within 2 years (24 months) prior to screening.
- Subject is a female who is pregnant, breast-feeding, or plans to become pregnant during the study.
- Subject is currently participating in another investigational drug, biologic or device trial, plans to participate in another investigational drug, biologic or device study during participation in this study, or has completed participation in another investigational drug, biologic or device trial within the last 30 days. Note: Subjects involved in extended follow-up trials for products that are currently commercially available and used as approved are not considered to be participating investigational trials.
- Subject is a staff member of any of the participating institutions or relative of a staff member.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: PVS-10200
Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
|
PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Major Adverse Events (MAEs)
Time Frame: within 4 weeks after study procedure
|
Major Adverse Events are: - Death - Major amputation - Procedural related serious adverse events - Investigational product related serious adverse events
|
within 4 weeks after study procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Major Adverse Events (MAEs)
Time Frame: within 24 and 48 weeks from study procedure
|
Major Adverse Events are: - Death - Major amputation - Procedural related serious adverse events - Investigational product related serious adverse events
|
within 24 and 48 weeks from study procedure
|
Incidence of Serious Adverse Events
Time Frame: Up to 48 weeks from study procedure
|
Up to 48 weeks from study procedure
|
|
Incidence of Adverse Events, Laboratory Abnormalities
Time Frame: Up to 48 weeks from study procedure
|
Up to 48 weeks from study procedure
|
|
Maintenance of Primary Patency of Superficial Femoral Artery (SFA)
Time Frame: within 4 weeks from study procedure
|
Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 4 weeks from study procedure
|
Maintenance of Primary Patency of Superficial Femoral Artery (SFA)
Time Frame: within 24 weeks from study procedure
|
Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 24 weeks from study procedure
|
Maintenance of Primary Patency of Superficial Femoral Artery (SFA)
Time Frame: within 48 weeks from study procedure
|
Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 48 weeks from study procedure
|
Rate of Binary In-stent Restenosis
Time Frame: within 4 weeks from study procedure
|
Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio >2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 4 weeks from study procedure
|
Rate of Binary In-stent Restenosis
Time Frame: within 24 weeks from study procedure
|
Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio >2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 24 weeks from study procedure
|
Rate of Binary In-stent Restenosis
Time Frame: within 48 weeks from study procedure
|
Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio >2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.
|
within 48 weeks from study procedure
|
Number of Patients Requiring Reintervention of Target Lesion / Target Vessel
Time Frame: up to 48 Weeks from study procedure
|
Survival analysis - outcome reported as patients requiring reintervention of the target lesion / vessel
|
up to 48 Weeks from study procedure
|
Resting Ankle-brachial Index
Time Frame: within 4, 24 and 48 weeks from study procedure
|
ABI was calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
This test is used to predict the severity of PAD.
|
within 4, 24 and 48 weeks from study procedure
|
Changes in Physical Exam
Time Frame: within 4, 24 and 48 weeks from baseline
|
Changes in physical examination were compared to baseline: numbers of subjects presenting any new finding or worsening of abnormal findings compared to the screening examination are reported
|
within 4, 24 and 48 weeks from baseline
|
The Fontaine Class of Peripheral Artery Disease
Time Frame: change from baseline to 4 weeks
|
CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene
|
change from baseline to 4 weeks
|
The Fontaine Class of Peripheral Artery Disease
Time Frame: change from baseline to 24 weeks
|
CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene
|
change from baseline to 24 weeks
|
The Fontaine Class of Peripheral Artery Disease
Time Frame: change from baseline to 48 weeks
|
CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene
|
change from baseline to 48 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PVS 03-001
- 2009-011998-32 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterSociety for Vascular SurgeryCompletedPeripheral Artery Disease (PAD)United States
Clinical Trials on PVS-10200
-
Basque Health ServiceCompletedQuality of Life | Cancer | Exercise | Functional CapacitySpain
-
Basque Health ServiceUnknownHealth Promotion | Health Behavior | Health Education | Patient Education | Counseling | Behavior TherapySpain
-
Assistance Publique - Hôpitaux de ParisAgence de La BiomédecineCompleted
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnRefractory Malignant AscitesUnited States
-
Allergy TherapeuticsInflamax Research Incorporated; Metronomia Clinical Research GMBHCompletedAllergic RhinitisUnited States
-
Hospital San Pietro FatebenefratelliNobel BiocareWithdrawnDental Implants | Dental Impression Materials | Dental Impression TechniquesItaly
-
Imperial College Healthcare NHS TrustBoston Scientific CorporationTerminated
-
Gustavo Avila-Ortiz DDS, MS, PhDCompleted
-
Gustavo Avila-Ortiz DDS, MS, PhDWithdrawnTooth Extraction Status NosUnited States